» Articles » PMID: 39993959

Integrative Disulfidptosis-Based Risk Assessment for Prognostic Stratification and Immune Profiling in Glioma

Overview
Journal J Cell Mol Med
Date 2025 Feb 24
PMID 39993959
Authors
Affiliations
Soon will be listed here.
Abstract

Disulfidptosis, a new form of programmed cell death, plays a role in multiple types of cancer. However, research on disulfidptosis in glioma is lacking. A disulfidptosis-associated risk score was constructed using Cox regression modelling, while LASSO regression was applied for feature selection. To explore the relationship between the risk score and the immune microenvironment, we employed CIBERSORT, ssGSEA and ESTIMATE algorithms. Additionally, wet lab experiments were conducted to validate the functional role of the key disulfidptosis gene RPN1, demonstrating its ability to promote glioma cell proliferation and migration. Disulfidptosis genes were significantly upregulated in gliomas, influencing clinical features and survival. The risk score effectively predicted OS and varied among clinical subgroups. High-risk scores correlated with tumour growth, invasion and immunosuppression. Patients with different risk scores showed distinct immune cell infiltration patterns. Most immune checkpoints and chemokines were positively associated with risk scores. Laboratory findings confirmed that RPN1 significantly promoted glioma cell proliferation and migration. Disulfidptosis-based risk assessment stratifies glioma prognosis and reveals immune microenvironment characteristics, offering insights for personalised treatment strategies.

References
1.
Ghouzlani A, Kandoussi S, Tall M, Reddy K, Rafii S, Badou A . Immune Checkpoint Inhibitors in Human Glioma Microenvironment. Front Immunol. 2021; 12:679425. PMC: 8301219. DOI: 10.3389/fimmu.2021.679425. View

2.
Lee J, Roh J . SLC7A11 as a Gateway of Metabolic Perturbation and Ferroptosis Vulnerability in Cancer. Antioxidants (Basel). 2022; 11(12). PMC: 9774303. DOI: 10.3390/antiox11122444. View

3.
Yamaguchi I, Yoshimura S, Katoh H . High cell density increases glioblastoma cell viability under glucose deprivation via degradation of the cystine/glutamate transporter xCT (SLC7A11). J Biol Chem. 2020; 295(20):6936-6945. PMC: 7242691. DOI: 10.1074/jbc.RA119.012213. View

4.
Wang T, Guo K, Zhang D, Wang H, Yin J, Cui H . Disulfidptosis classification of hepatocellular carcinoma reveals correlation with clinical prognosis and immune profile. Int Immunopharmacol. 2023; 120:110368. DOI: 10.1016/j.intimp.2023.110368. View

5.
Polewski M, Reveron-Thornton R, Cherryholmes G, Marinov G, Cassady K, Aboody K . Increased Expression of System xc- in Glioblastoma Confers an Altered Metabolic State and Temozolomide Resistance. Mol Cancer Res. 2016; 14(12):1229-1242. PMC: 6237285. DOI: 10.1158/1541-7786.MCR-16-0028. View